Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab | Zendy

Noriko Fujita | Zendy; Yukie Enomoto | Zendy; Keiko Inakami | Zendy; Tetsu Yanagisawa | Zendy; Chikage Iguchi | Zendy; Toyokazu Aono | Zendy; Takashi Nomura | Zendy; Hitoshi Yamamoto | Zendy; Tsutomu Kasugai | Zendy; Eiichi Shiba | Zendy

Open Access

Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab

Author(s) -

Noriko Fujita,

Yukie Enomoto,

Keiko Inakami,

Tetsu Yanagisawa,

Chikage Iguchi,

Toyokazu Aono,

Takashi Nomura,

Hitoshi Yamamoto,

Tsutomu Kasugai,

Eiichi Shiba

Publication year - 2019

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000502910

Subject(s) - trastuzumab , medicine , pertuzumab , breast cancer , oncology , hazard ratio , proportional hazards model , chemotherapy , cancer , gastroenterology , confidence interval

It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast cancer patients and those after NAC among patients who did not achieve pathological complete response (pCR) using conventional adjuvant trastuzumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research